Beigene (NASDAQ:ONC) Shares Up 4.2% – What’s Next?

Beigene, Ltd. (NASDAQ:ONC) shot up 4.2% during trading on Friday . The stock traded as high as $274.00 and last traded at $273.67. 80,645 shares changed hands during trading, a decline of 82% from the average session volume of 440,196 shares. The stock had previously closed at $262.60.

Analysts Set New Price Targets

Several research firms have recently weighed in on ONC. JMP Securities set a $348.00 target price on shares of Beigene in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a report on Thursday, March 13th. Guggenheim restated a “buy” rating on shares of Beigene in a research report on Friday, February 28th. Macquarie upped their price objective on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, Bank of America raised Beigene from a “neutral” rating to a “buy” rating and raised their price objective for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Price Performance

The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $26.38 billion, a P/E ratio of -32.45, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Insider Buying and Selling at Beigene

In other Beigene news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John Oyler sold 101,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $244.30, for a total transaction of $24,674,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,052,367 shares of company stock worth $270,454,249. 7.43% of the stock is currently owned by insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.